ArticleDiscover oncology2026
Single cell and multi-omics analysis reveal senescence-related molecular subtypes and a prognostic signature in clear cell renal cell carcinoma.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundClear cell renal cell carcinoma (ccRCC) is the most prevalent subtype of renal cancer and represents high heterogeneity and poor prognosis. Current evidence highlights that the senescence program, particularly through SASP, can simultaneously impose tumor-suppressive barriers and, under specific conditions, support malignant progression. Nevertheless, the comprehensive characterization and clinical significance of cellular senescence in ccRCC have yet to be fully elucidated.
methodsWe integrated single-cell and bulk transcriptomic data to characterize senescence-associated features in ccRCC. Single-cell RNA sequencing (scRNA-seq) data from normal, peritumoral, and tumor tissues (GSE222703 and GSE210042) were used to assess SASP signatures across cell types. Differentially expressed senescence-associated genes (SAGs) were identified from TCGA-KIRC and used for consensus clustering. A risk score model was constructed using Random Survival Forest (RSF) based on key SAGs and validated across three independent cohorts [TCGA-KIRC (n = 537), E-MTAB-1980 (n = 101), and CPTAC-ccRCC (n = 105)]. Immune cell infiltration, clinical associations, and prognostic utility were further evaluated. A nomogram was developed and tested for survival prediction.
resultsSenescence signatures were enriched in epithelial tumor cells, especially in ccRCC tissues compared to normal and peritumoral tissues. Two distinct molecular subtypes (C1 and C2) were defined by SAG expression, with C1 exhibiting stronger senescence activity and better survival outcomes. The RSF-based risk score showed robust performance across all cohorts and was independently associated with survival. High-risk patients displayed lower immune activation, reduced antigen presentation, and a more immunosuppressive microenvironment. A survival nomogram integrating the risk score with clinical parameters achieved high predictive accuracy. Among all SAGs, ALDH18A1 was identified as a key prognostic gene and was significantly upregulated in ccRCC. In addition, single-cell sequencing analysis revealed substantial interactions between ALDH18A1
conclusionsIn this study, we uncovered the diverse patterns of cellular senescence within ccRCC and developed a senescence-derived risk score that demonstrated strong prognostic value. Moreover, ALDH18A1 was identified as a promising biomarker for prognosis and a potential therapeutic target in ccRCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.